cyrilzakka/clinical-trials huggingface dataset:
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC


Eligibility Criteria:
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

* ECOG Performance Status (PS) \<=1
* Histologically or cytologically confirmed, stage IIIB (malignant pleural effusion), stage IV or recurrent NSCLC
* Measurable disease by RECIST guidelines

Exclusion Criteria:

* Evidence of predominantly squamous-cell histology
* Known CNS metastases
* Any prior antineoplastic systemic regimens for NSCLC
* Excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident
* Gross hemoptysis (≥1/2 tsp of red blood)
* Uncontrolled hypertension
* Clinically significant cardiovascular disease
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis
Validation of the EEG Signal Quality Measured by the URGOnight Device and Comparison With a Clinical Device

The electroencephalogram or EEG is a painless and non-invasive exploratory examination routinely performed in clinical and experimental medicine and has various applications. It is therefore relevant to develop application-specific EEG measurement devices.

The clinical development of therapies based on brain control has led to the emergence of numerous EEG devices that aim to allow mobile, autonomous, and easy use for users.

Data from the literature have proven the ability of neurofeedback (a form of biofeedback in which subjects respond to a display of their own brainwaves in order to improve their health or performance) to improve brain function in healthy or pathological subjects.

These therapeutic applications are offered in hospital settings with conventional systems and in the presence of a therapist.

The EEG measurement device URGOnight was developed with the aim of offering autonomous neurofeedback exercises at home. URGOnight is a portable device. It uses passive electrodes (which do not send an electric current) and so-called dry electrodes, i.e. no gel or conductive paste is required.

Therefore, the SIGMA study aims to evaluate the quality of the EEG signal collected by URGOnight and compare it with an electroencephalography device commonly used in clinical and research settings.

We will also evaluate the quality of the brain wave measurement usually retained in comparative studies of EEG systems.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old
* Head circumference between 52 and 62 centimeters
* Affiliated or beneficiary of a social security system
* Protected persons in the sense of article L.1121-9 of the Public Health Code.

Exclusion Criteria:

* According to declarative :
* Use of medication or drugs with a possible effect on cognitive performance, such as benzodiazepines, antidepressants and antipsychotics
* Epilepsy
* The experimenter cannot get a good signal between the scalp and the electrodes at the beginning of the experiment (for example because of the type of hair or for any other technical reason).
Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS

Our recent study (Xie et al, Neurology 2015; 84: 415-420) found that bilateral STN DBS of 60Hz, compared to the traditional 130Hz, decreased the aspiration frequency and swallowing difficulty, freezing of gait (FOG), and other axial symptoms and parkinsonism in Parkinson patients with FOG refractory to 130Hz and medications. The benefit of 60Hz stimulation persisted during the 6-week study period, but with worsening tremor in one patient. However, it remains unknown whether the benefit of 60Hz would persist on prolonged stimulation period, and whether there is carry-over effect across different conditions. Hence, the investigators would like to test the hypothesis that the 60Hz stimulation, compared to 130Hz might have persistent benefit over an extended period in reducing the swallowing dysfunction, FOG, and other axial symptoms in these PD patients even after correcting the potential carry-over effect.

The investigators will enroll 14 Parkinson patients with bilateral STN DBS and refractory FOG to 130Hz stimulation and dopaminergic medications for two visits of at least 6-month apart. The 6 patients remaining on 60Hz stimulation after our previous study consisting of 7 patients will be assessed once again as visit-2 after previous visit-1 of their last study. We anticipate to have 20 patents complete for visit-1 and at least 18 patients complete for visit-2 in this randomized double-blind prospective crossover study with their usual medication "on" state, with 6-7 patients on each starting condition (60Hz vs 130Hz vs DBS off). Swallowing function on modified barium swallowing test and swallowing questionnaire, FOG in stand-walk-sit test and questionnaire, and other axial and motor function on UPDRS-III will be assessed under each DBS condition. Changes in measurements between 60Hz and 130Hz at each visit and under 60Hz between two visits will be analyzed, with swallowing function and FOG as primary, and the rest as secondary outcomes, correcting for potential carryover effect. Changes between other DBS conditions might also be explored in this 2-year study.

This would be the first study on the long-term effect of 60Hz stimulation on dysphagia, FOG and other axial and motor symptoms in Parkinson patients with bilateral STN DBS and FOG refractory to 130Hz stimulation and dopaminergic medications, which will have significant impact on the treatment of difficult axial symptoms of high morbidity and mortality.

Eligibility Criteria:
Inclusion Criteria:

* PD patients with bilateral STN DBS placement and FOG at 130Hz even at usual medication "on" state.

Exclusion Criteria:

* Known history of recent aspiration pneumonia
Dietary Intake and Eating Habits During the COVID-19 Pandemic

The COVID-19 pandemic affects eating habits, diet quality and physical activity differently among individuals; it is unclear how these behaviours will evolve as the pandemic continues. In this observational study, dietary intake will be frequently collected using an artificial intelligence (AI)-enhanced mobile application combined with real-time analysis, and lifestyle behaviours from online questionnaires, to provide timely, relevant data for public health decision making.

A thousand nine hundred and twenty adult men and women aged 18 years and older, living in the community and owning a smartphone or tablet, will be recruited all over Canada. Rapid recruitment will be achieved using social media and professional networks. All data will be collected online to allow a broad reach even in remote regions. Self-reported eating habits, physical activity, sleep, alcohol consumption, anxiety and depression data will be collected using validated questionnaires on an online survey platform, and dietary intake data using the mobile application Keenoa. With the application, participants take pictures of their meals, which are analyzed and accessible to researchers in real-time, providing comprehensive data on nutrient and food intake, and hence patterns and diet quality. Diet will be tracked for a full week at study entrance and repeated 6 times during a year, and once one year later, along with follow-up questionnaires on lifestyle behaviours.

The main study objectives are 1) to evaluate how eating habits, diet quality and related lifestyle behaviours of Canadian adults are impacted by confinement phases of the pandemic over one year; and 2) determine the association between eating behaviours and diet quality with contextual socio-demographic, education, emotional and health factors, and identify emerging explanatory factors as clusters.

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged 18 years and over, living in Canada
* Owning a smartphone and having access to internet
* Able to read and understand English or French

Exclusion Criteria:

* Any active and uncontrolled acute disease that interferes with usual food intake
* Being hospitalized
* Pregnancy or lactation
BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biopsies of the prostate (TRNBP).


Eligibility Criteria:
Inclusion Criteria:

* Transrectal needle biopsy of the prostate required.
* A clean-catch midstream-urine (MSU) culture negative (\<104 CFU/mL) for possible pathogens at the Pre-Therapy Visit prior to the TRNBP.
* Gastrointestinal absorption is adequate as evidenced by passage of gas or feces per rectum and patient can tolerate oral food, fluids, and medication without vomiting or diarrhea.

Exclusion Criteria:

* History of hypersensitivity to ciprofloxacin or other quinolone antibiotics
* Valvular heart disease that requires antibiotic prophylaxis to prevent bacterial endocarditis
* Concomitant use of theophylline, probenecid, or warfarin at any time during the entire study
* Renal insufficiency
* Known or suspected central nervous system disorder that may predispose to seizures or lower the seizure threshold
* Absolute neutrophil count (ANC) \<1000/mm3
* Human immunodeficiency virus (HIV) infection with a CD4 count \<200 cells/micL. HIV testing is NOT required
* Antibiotic administration within one week of the TRNBP
* Severe hepatic insufficiency (Child-Pugh C)
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

The purpose of this study is to determine the effects of LX4211 and metformin on each other when given at the same time as single doses to healthy human subjects.


Eligibility Criteria:
Inclusion Criteria:

* Adults ≥18 to ≤55 years of age. Females must be of non-childbearing potential.
* Body mass index (BMI)≥18 to ≤35 kg/sq m
* Able to provide written consent
* Vital signs within sponsor-defined ranges

Exclusion Criteria:

* Use of any medication, including any prescription, over-the-counter, herbal tea, or other supplements within 5 days of dosing
* No investigational agent or study treatment within 30 days prior to Day 1.
* No protein or antibody-based therapeutic agents within 3 months prior to screening
* Use of any tobacco product
* History of bariatric surgery or any gastrointestinal surgery that may induce malabsorption
* History of any major surgery within 6 months prior to screening
* History of any serious adverse reaction or hypersensitivity to metformin or LX4211.
* History of renal disease or significantly abnormal kidney function test
* History of hepatic disease or significantly abnormal liver function test
* History of any active infection within 30 days prior to Day 1
* History of any surgical or medical condition or clinically significant laboratory or physical finding
* Positive urine glucose at Screening
* Use of drugs or alcohol
Allogeneic Cell Therapy for Adults With Hematologic Malignancies

This is a research study involving the treatment of leukemia or lymphoma (lymph gland cancer) in adults who have leukemia or lymphoma that is unlikely to be cured with regular anticancer drugs or radiation treatments.

This is a research study involving the treatment of leukemia or lymphoma (lymph gland cancer) in adults who have leukemia or lymphoma that is unlikely to be cured with regular anticancer drugs or radiation treatments. Intensive treatment with high doses of chemotherapy followed by a bone marrow transplant (BMT) from an HLA-(tissue-type) matched related donor would provide the best chance for cure of this leukemia or lymphoma. However, the success of BMT from relatives is limited in patients who are older than 50 years and/or have organ dysfunction by substantial complications due to the high dose chemotherapy related toxicity, graft-versus- host disease (GVHD), and relapse. Patients eligible for this study have an HLA matched sibling, but a BMT from the sibling would carry a high risk for severe side effects due to the patient's age, and/or organ dysfunction.

Researchers are evaluating a new treatment for adult patients with leukemia and lymphoma which involves regular dose chemotherapy and blood stem cell transplantation from an HLA-matched relative, with injections of donor immune cells (a type of white blood cells) given if you later relapse. In this study, the safety and feasibility of this treatment strategy are being investigated.

Eligibility Criteria:
Inclusion Criteria:

* To be eligible as a recipient for this study, patients must have chronic myelocytic leukemia (CML) in chronic phase and be older than 60 years of age, have advanced myelodysplastic syndrome (MDS) and be over 60 years of age, have chronic lymphocytic leukemia (CLL) and be over 50 years of age, or have low grade lymphoma and be over 50 years of age. HLA typing of the recipient's family will be used to identify potential donors. Please contact study nurse for additional eligibility criteria. Final eligibility will be determined by the health professionals conducting this clinical trial.

Exclusion Criteria:

* Patients with an active, invasive/systemic fungal infection and patients with serologic evidence of antibodies to HIV I/II will be excluded from participating as recipients in this study. Additional exclusion factors include: patients who are pregnant or lactating, those with active central nervous system (CNS) malignant disease, and patients whose life expectancy is limited by diseases other than the disease for which the transplant is being performed. Please contact study nurse for additional ineligibility criteria. Final eligibility will be determined by the health professionals conducting this clinical trial.
Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma

The impact of anti-platelet drugs on the concentrations of Brain-derived neurotrophic factor (BDNF) in human plasma and serum is unknown. It is the aim of this study to investigate the impact of a single dose of Aspirin (500 mg) or Clopdigrel (600 mg) on the concentrations of Brain-derived neurotrophic factor (BDNF) in plasma and serum of healthy volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-50 years
* Gender: Male

Exclusion Criteria:

* Any acute disease
* Any chronic disease
* Any medication
* Allergies / Intolerance in association with Aspirin or Clopidogrel
Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)

The main objective is to evaluate the interest of the repeated measurement of procalcitonin in patients with pulmonary infection to reduce the duration of antibiotic therapy in comparison with a conventional clinical strategy.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 80 years
* Started antibiotics for a chest infection
* Procalcitonin performed J0 antibiotic treatment
* Person affiliated to the social security

Exclusion Criteria:

* Patients with a documented infection with germs after Listeria spp, Legionella pneumophilia, Mycobacterium tuberculosis
* Patients with a documented infection with a virus or parasite (eg hemorrhagic fever, malaria)
* Patients with endovascular infection associated (endocarditis, pacemaker. Intravascular catheter)
* Patients with lung abscess associated upon entry Patients with a chronic infection associated
* Patients with severe immunosuppression (HIV or transplant)
* Palliative patient
* Death within 24 hours of admission to nursing units.
* Presence of antibiotic treatment for chronic infection.
* Patient under guardianship, curatorship or any other administrative or judicial action or deprivation of the right or freedom
* Patients hospitalized without their consent
Nourishing the Community Through Culinary Medicine- Acres Homes

The purpose of this study is to to implement adapted virtual Culinary Medicine (CM) curriculum among target population, to assess if program participation improves participant dietary behaviors, nutrition knowledge, and cooking skills and behaviors above standard of care, to assess if program participation improves patient levels of HbA1c, Body Mass Index, Blood Pressure, HDL, LDL and Triglycerides above standard of care and to determine the feasibility and reproducibility of virtual synchronous CM classes.


Eligibility Criteria:
Inclusion Criteria:

* Receiving care at UT Physicians clinics
* diagnosed with type 2 diabetes and elevated body mass index (\>=25)
* HbA1c labs and clinic-assessed weight completed within the last 3 months;
* English speaking or Spanish speaking.
* Can obtain groceries before each class (intervention group only)

Exclusion Criteria:

* Patients without the technological support needed to participate (e.g., reliable internet and device - cell phone, tablet or laptop);
* Patients with an uncontrolled impairment that interferes with ability to participate.
A Comparison of McGrath, Pentax and Macintosh Laryngoscopes for Nasotracheal Intubation in Pediatrics

Videolaryngoscope provide better view of the larynx. This better view could improve the navigation of endotracheal tube in nasotracheal intubation. Contrast to the improved result in adult, one previous report using Glidescope in children did not show better performance than direct laryngoscope. The aim of this study is to compare the performance of McGrath, Pentax and Macintosh laryngoscope for nasotracheal intubation in children.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologist physical status class I, II

Exclusion Criteria:

* abnormality of airway
* bleeding tendency
Vascular Inflammation Stratified by Body Size Phenotype

* Vascular Inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18FDG-PET is a promising novel tool for identifying and quantifying vascular inflammation within atherosclerotic plaque
* Recently, unique subsets of obese individuals, such as metabolically obese but normal weight (MONW) and metabolically healthy obese (MHO), have been getting an attention
* Therefore, the purpose of this study is to examine the relationship of vascular inflammation,measured by FDG-PET, with various body sized phenotypes


Eligibility Criteria:
Inclusion Criteria:

* Healthy patients for visiting routine medical check in our clinic

Exclusion Criteria:

* history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
* stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
* history of inflammatory conditions that affect the study results
* taking medications that might affect inflammatory status, including steroid and non-steroidal anti-inflammatory drug within 6 months
* or malignancy or severe renal or hepatic disease
SEMA4C as a Relapse Biomarker in Breast Cancer

Breast cancer remains the most common cancer in women worldwide. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The objective of this study is to investigate SEMA4C's potential role as an early relapse biomarker in breast cancer.

Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Although regular clinical examination, mammography, ultrasonography, and magnetic resonance imaging can detect some recurrence patients, the lack of robust biomarkers for monitoring of anti-tumor therapies and detection of recurrence reduce the treatment effectiveness of current strategies for breast cancer.

Semaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. The study is undertaken to explore SEMA4C's potential role as an early relapse biomarker in breast cancer.

Eligibility Criteria:
Inclusion Criteria:

* Have histologically confirmed new diagnosis of breast cancer according to biopsy or surgery

Exclusion Criteria:

* Patients who are not mentally capable of giving written informed consent
* Serum samples doesn't qualified
* Patients who refuse follow-up on their conditions
* Patients with prior cancer history
* Patients with a diagnosis of other severe acute or chronic medical may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study